Valeant Pharmaceuticals International (NYSE:VRX) traded higher in the last at $22.62, gaining 0.1 points or 0.44%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-2.12) million. The composite uptick value of $2.18 million was eclipsed by the accrued downtick value of $4.3 million, thereby ensuring the up/down ratio of 0.51. For the week, the shares have posted returns of 2.62%.A block trade registered during the day has revealed $0 million in upticks and $1.84 million in downticks. The up/down ratio in this case turned out to be 0. The net money flow for the block trade was $(-1.84) million.
The stock has recorded a 20-day Moving Average of 16.27% and the 50-Day Moving Average is 25.94%. The company shares have dropped 90.35% in the past 52 Weeks. On August 6, 2015 The shares registered one year high of $263.81 and one year low was seen on June 20, 2016 at $21.77. The 50-day moving average is $27.3 and the 200 day moving average is recorded at $59.74. S&P 500 has rallied 1.93% during the last 52-weeks.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $22.45 on Tuesday but the bulls could not build on the opening and the stock topped out at $22.91 for the day. The stock traded down to $21.41 during the day, due to lack of any buying support eventually closed down at $21.64 with a loss of -3.91% for the day. The stock had closed at $22.52 on the previous day. The total traded volume was 28,330,550 shares.
Currently the company Insiders own 8.62% of Valeant Pharmaceuticals International shares according to the proxy statements. Institutional Investors own 78.75% of Valeant Pharmaceuticals International shares. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Valeant Pharmaceuticals International, Inc., Papa Joseph C had purchased shares worth of $4,944,960 in a transaction dated on June 10, 2016. A total of 202,000 shares were purchased at a price of $24.48 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.